FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

WANG HUIMIN
2. Issuer Name and Ticker or Trading Symbol

Edwards Lifesciences Corp [ EW ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
CVP, Japan & Intercontinental
(Last)          (First)          (Middle)

ONE EDWARDS WAY
3. Date of Earliest Transaction (MM/DD/YYYY)

5/1/2012
(Street)

IRVINE, CA 92614
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/1/2012     M (1)    20728.0000   A $21.9550   72293.0000   (2) D    
Common Stock   5/1/2012     S (1)    20728.0000   D $85.0300   (3) 51565.0000   (2) D    
Common Stock   5/2/2012     M (1)    19272.0000   A $21.9550   70837.0000   (2) D    
Common Stock   5/2/2012     S (1)    8358.0000   D $85.6800   (4) 62479.0000   (2) D    
Common Stock   5/2/2012     S (1)    10914.0000   D $86.5200   (5) 51565.0000   (2) D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Acquire)   $21.9550   5/1/2012     M   (1)       20728.0000    5/11/2007   5/10/2013   Common Stock   20728.0000   $0.0000   69272.0000   (2) D    
Employee Stock Option (Right to Acquire)   $21.9550   5/2/2012     M   (1)       19272.0000    5/11/2007   5/10/2013   Common Stock   19272.0000   $0.0000   50000.0000   (2) D    

Explanation of Responses:
( 1)  The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 2, 2011.
( 2)  This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.
( 3)  This transaction was executed in multiple trades at prices ranging from $85.03 to $85.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
( 4)  This transaction was executed in multiple trades at prices ranging from $85.16 to $86.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
( 5)  This transaction was executed in multiple trades at prices ranging from $86.16 to $87.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
WANG HUIMIN
ONE EDWARDS WAY
IRVINE, CA 92614


CVP, Japan & Intercontinental

Signatures
/s/ Denise E. Botticelli, Attorney-in-Fact 5/3/2012
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Edwards Lifesciences (NYSE:EW)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Edwards Lifesciences Charts.
Edwards Lifesciences (NYSE:EW)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Edwards Lifesciences Charts.